PEDIATRIC BRAIN ACNS 0332: Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-Apoptotic Agent in other than Average Risk Medulloblastoma/PNET Patients. https://clinicaltrials.gov/ct2/show/nct00392327?term=0332&rank=6 ACNS 02B3: Children's Oncology Group (COG) Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens. https://clinicaltrials.gov/ct2/show/nct00919750?term=02b3&rank=1 ACNS 0831: Randomized Trial of Post-Radiation Chemotherapy in Patients with newly Diagnosed Ependymona Ages 1-21 Years: A Group wide Phase III Study. https://clinicaltrials.gov/ct2/show/nct01096368?term=acns+0831&rank=1 ACNS 1123: Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS-GCT). https://clinicaltrials.gov/ct2/show/nct01602666?term=acns+1123&rank=1 COMPANION STUDIES ACCRN 07: Protocol for the Enrollment on the Official COG Registry, the Childhood Cancer Research Network (CCRN). https://clinicaltrials.gov/ct2/show/nct01117168?term=protocol+for+the+enrollment+on+the+official+cog+re gistry&rank=1 POG 9902: COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol. https://clinicaltrials.gov/ct2/show/nct00919269?term=pog+9902&rank=1
ABTR 01B1: COG Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors. https://clinicaltrials.gov/ct2/show/nct00898079?term=abtr+01b1&rank=2 ALTE 07C1: Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer. https://clinicaltrials.gov/ct2/show/nct00772200?term=alte+07c1&rank=1 ALTE 1621: Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial https://clinicaltrials.gov/ct2/show/nct02717507?term=alte+1621&rank=1 CANCER CONTROL ALTE 05N1: Umbrella Long-Term Follow-Up Protocol. https://clinicaltrials.gov/ct2/show/nct00736749?term=alte+05n1&rank=1 NEUROBLASTOMA & OTHER EMBRYONAL TUMORS ANBL 00B1: Neuroblastoma Biology Studies. https://clinicaltrials.gov/ct2/show/nct01117168?term=cog+registry&rank=1 ANBL1221: Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864, IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 623408, IND# 4308) in Children with Refractory, Relapsed or Progressive Neuroblastoma. https://clinicaltrials.gov/ct2/show/nct01767194?term=anbl1221&rank=1 ANBL1232: Utilizing Response and Biology-Based Risk Factors to Guide Therapy in Patients with Non- High-Risk Neuroblastoma. https://clinicaltrials.gov/ct2/show/nct02176967?term=anbl1232&rank=1
LYMPHOMAS/HODGKIN S DISEASE AHOD1331: Randomized Study of Brentuximab Vedotin (SGN-35, IND # 117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (chl) in Children and Adolescents. https://clinicaltrials.gov/ct2/show/nct02166463?term=ahod1331&rank=1 ANHL12P1: Randomized Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC# 749005, commercially labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL). https://clinicaltrials.gov/ct2/show/nct01979536?term=anhl12p1&rank=1 NATIONAL WILM S TUMOR STUDY POG 9442: National Wilms Tumor Late Effects Study. https://clinicaltrials.gov/ct2/show/nct00736749?term=alte05n1&rank=1 AREN03B2: Renal tumors Classification, Biology, and Banking Study. https://clinicaltrials.gov/ct2/show/nct00898365?term=aren03b2&rank=1 HEPATOBLASTOMA TUMORS AHEP 0731: Treatment of Children with All Stages of Hepatoblastoma. https://clinicaltrials.gov/ct2/show/nct00980460?term=ahep+0731&rank=1 MULTI DISEASE SITES ADVL 1522: Study of IMGN901 (Lorvotuzumab Mertansine; IND# 126953, NSC# 783609) in Children with Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor (MPNST) and Synovial Sarcoma. https://clinicaltrials.gov/ct2/show/nct02452554?term=advl+1522&rank=1
APEC 14B1: The Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study. https://clinicaltrials.gov/ct2/show/nct02402244?term=14b1&rank=1 BONE & SOFT TISSUE SARCOMAS AOST 06B1: A Children's Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens. https://clinicaltrials.gov/ct2/show/nct00899275?term=aost+06b1&rank=1 AEWS 07B1: A Children's Oncology Group Protocol for Collecting and Banking Ewing Sarcoma Specimens. https://clinicaltrials.gov/ct2/show/nct00899990?term=aews+07b1&rank=1 AEWS 1031: Randomized Trial of Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma. https://clinicaltrials.gov/ct2/show/nct01231906?term=aews+1031&rank=1 AEWS 1221: Randomized Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND # 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma. https://clinicaltrials.gov/ct2/show/nct02306161?term=aews+1221&rank=1 AOST 1321: Phase 2 Study of Denosumab (IND#127430, NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma https://clinicaltrials.gov/ct2/show/nct02470091?term=aost+1321&rank=1 ARST 1321: Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS), a Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613) https://clinicaltrials.gov/ct2/show/nct02180867?term=arst+1321&rank=1
LEUKEMIA (ALL) AALL 05B1: COG Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens. https://clinicaltrials.gov/ct2/show/nct00897325?term=aall+05b1&rank=1 AALL 08B1: Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL). https://clinicaltrials.gov/ct2/show/nct01142427?term=aall+08b1&rank=2 AALL 0932: Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B- ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy). https://clinicaltrials.gov/ct2/show/nct01190930?term=aall+0932&rank=1 AALL 1131: Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (B-ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum Including a stratum evaluating Dasatinib (IND# 73789, NSC# 732517) in patients w/ Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations https://clinicaltrials.gov/ct2/show/nct02883049?term=aall+1131&rank=1 AALL 1231: Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy). https://clinicaltrials.gov/ct2/show/nct02112916?term=aall+1231&rank=1 AALL 1331: Risk-Stratified Randomized Testing of Blinatumomab (IND# 117467, NSC# 765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) https://clinicaltrials.gov/ct2/show/nct02101853?term=aall+1331&rank=1 LEUKEMIA (AML) AAML 08B1: Biology Study of Transient Myeloproliferative Disorder (TMD) in Children with Down Syndrome (DS). https://clinicaltrials.gov/ct2/results?term=aaml+08b1&search=search
AAML 1031: Randomized Trial for Patients with de novo AML Using Bortezomib and Sorafenib (IND# 114480; NSC# 681239; NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD. https://clinicaltrials.gov/ct2/show/nct01371981?term=aaml+1031&rank=1 AAML 1331: A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid https://clinicaltrials.gov/ct2/show/nct02339740?term=aaml+1331&rank=1 AAML 1531: Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome (DS). https://clinicaltrials.gov/ct2/show/nct02521493?term=aaml+1531&rank=1